Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Twist Bioscience Corp — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.59, while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | TWST | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.96 | $102.88 |
52-Week Low | $12.03 | $24.16 |
Market Cap | — | $5.45B |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.41, showing modest daily gains of 0.4%. The ETF employs a covered call strategy on NVIDIA shares, generating weekly distributions but capping upside potential. Technical indicators signal bearish momentum with moving averages and ADX pointing downward, while oscillators remain neutral. Recent distributions have ranged from $0.10 to $0.21 per share, providing income-focused investors with regular cash flow.
The outlook remains challenging as the covered call strategy sacrifices NVIDIA's explosive growth potential for income generation. Key risks include opportunity cost from missed upside, fund management fees, and dependence on NVIDIA's volatility. While attractive for income seekers, growth-oriented investors may prefer direct NVIDIA exposure given the significant performance trade-off.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
